TABLE 2.
Specific antiosteoporotic drug treatments
| Follow‐up population | Hip (n = 208,102) | Vertebra (n = 31,979) | Pelvis (n = 38,051) | Multiple ribs (n = 17,184) | Proximal humerus (n = 52,468) | Total (n = 347,784) |
|---|---|---|---|---|---|---|
| Before index fracture, n (%) | ||||||
| At least one delivery | 32,930 (15.8) | 6125 (19.2) | 9270 (24.4) | 2200 (12.8) | 8761 (16.7) | 59,286 (17.0) |
| At time of index fracture | 15,273 (7.3) | 3390 (10.6) | 5056 (13.3) | 1203 (7.0) | 4450 (8.5) | 29,372 (8.4) |
| During 12 months after index fracture, n (%) | ||||||
| At least one delivery | 31,385 (15.1) | 8250 (25.8) | 8683 (22.8) | 1775 (10.3) | 8127 (15.5) | 58,220, (16.7) |
| Treatment continued a | 15,273 (7.3) | 3390 (10.6) | 5056 (13.3) | 1203 (7.0) | 4450 (8.5) | 29,372 (8.4) |
| Treatment restarted b | 4048 (1.9) | 1112 (3.5) | 1166 (3.1) | 196 (1.1) | 1098 (2.1) | 7620 (2.2) |
| Treatment initiated c | 12,064 (5.8) | 3748 (11.7) | 2461 (6.5) | 376 (2.2) | 2579 (4.9) | 21,228 (6.1) |
a
Treatment continued: treatment ongoing at time of index fracture and delivery continuing without interruption thereafter.
b
Treatment restarted: delivery of a previous treatment after the index fracture, following a period of interruption.
c
Treatment initiation (no treatment in the 2 years preceding the index fracture and first delivery documented after the index fracture.